Clsi Document M45 Pdf May 2026

I can’t directly provide or link to the CLSI document M45 (usually Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria) as a PDF, since it is a copyrighted document sold by the Clinical and Laboratory Standards Institute (CLSI). However, I can write a useful, practical article summarizing its purpose, scope, and key applications in clinical microbiology.

Below is a detailed, original guide based on the standard’s known principles.

Practical Laboratory Implementation

• Algorithmic approach: Implement a testing algorithm: initial screening based on indicator antibiotics → reflex confirmatory or molecular testing when indicated → apply reporting rules and interpretive comments.
• Quality control: Follow CLSI QC procedures and use appropriate control strains for screening and confirmatory tests.
• Communication: Ensure laboratory reports include interpretive notes that clearly state limitations of in vitro susceptibility in presence of ESBLs and recommended therapeutic considerations.

4. Interlibrary Loan (Limited)

Some medical libraries may loan a print copy, but PDFs cannot be legally shared due to DRM restrictions.

3. Gradient Diffusion (Etest)

• Not a reference method, but M45 notes it can be used if correlation with BMD has been verified by the lab. No official breakpoints; refer to BMD MIC equivalents.

Consequences of using an invalid PDF:

• Accreditation citation: CAP requires current CLSI methods. An inspector will ask for your license or proof of purchase.
• False resistance: An old M45 PDF might list a breakpoint of ≤1 µg/mL for susceptible, while the current version is ≤0.5 µg/mL. You would call a resistant strain "susceptible," leading to treatment failure.
• Legal liability: In malpractice cases, plaintiffs' attorneys will subpoena your method references. Using a pirated, outdated PDF is indefensible.

Final Word

The CLSI document M45 PDF is more than just a file—it is a lifeline for clinical microbiologists facing the diagnostic challenge of fastidious, infrequent, and dangerous bacteria. Respect its guidelines, keep your copy current, and never hesitate to reference it when the unusual arrives at your lab bench.

Pro-tip: Bookmark the official CLSI store page for M45. And remember – a legitimate PDF is an investment in quality patient care.

Disclaimer: This article is for informational purposes. Always refer to the most current official CLSI publication for actual testing and interpretation. CLSI, M45, and related trademarks are property of the Clinical and Laboratory Standards Institute.

The CLSI M45 document (3rd Edition) provides standardized broth microdilution and disk diffusion susceptibility testing methods for fastidious and infrequently isolated bacteria. It serves as a critical guide for testing pathogens, such as Corynebacterium Campylobacter

spp., to guide effective antibiotic treatment. For more information, visit

Why M45 Matters

Most clinical microbiology labs are familiar with CLSI M100 (for rapidly growing aerobes) and M07 (dilution methods). But what about fastidious organisms that don’t grow well on routine media or infrequently isolated pathogens with no standardized testing guidance elsewhere?

That’s where CLSI document M45 fills a critical gap. It provides consensus-based methods for antimicrobial susceptibility testing (AST) of bacteria that are:

• Difficult to culture (e.g., require special atmospheres or supplements)
• Rarely encountered in most clinical labs
• Lacking FDA-cleared commercial AST panels

Overview — CLSI M45 (Susceptibility Testing of Antimicrobial Agents for Bacteria That Produce Extended-Spectrum β-Lactamases)

CLSI document M45 provides guidance on antimicrobial susceptibility testing (AST) and interpretation for Enterobacterales that produce extended-spectrum β-lactamases (ESBLs) and other β-lactamases that compromise β-lactam therapy. It focuses on practical laboratory methods, breakpoints, reporting recommendations, and interpretive comments to improve clinical relevance and patient care when dealing with ESBL-producing organisms.

Key Concepts

• ESBL definition: Enzymes that hydrolyze oxyimino-cephalosporins (e.g., cefotaxime, ceftazidime) and monobactams and are inhibited by β-lactamase inhibitors (e.g., clavulanic acid). They can be plasmid-encoded and often co-carriage with other resistance determinants.
• Phenotypic complexity: Presence of ESBLs can be masked by coexisting mechanisms (e.g., AmpC, porin loss, carbapenemases), causing variable AST results and complicating detection.
• Breakpoint strategy: CLSI recommends using antimicrobial agent-specific breakpoints and interpretive guidance rather than relying on a single ESBL screen for reporting therapy-susceptible results.